

# OUR KEY ACHIEVEMENTS IN 2024

as of 31 December 2024

## Bridging the drug development gap

### Development of People



**12** Fellows in-training  
Under the NRF Innovation & Enterprise Fellowship Programme

**407** Record attendance at our Annual Drug Discovery & Development Symposium

**5** Workshops & seminars conducted

**12** STDR<sup>1</sup> Pre-Pilot stream 1 teams trained on the development of single assets

### Development of Projects and Knowledge



**4** Proposals Awarded through STDR\* and mentored by EDDC

**11** Grant-funded Collaborations  
Including ETC-159 Investigator-Initiated Trial



**9** Scientific Publications

**2** World's Top 2% Scientists 2024 by Stanford University

## Advancing Projects



**EBC-129**  
**Phase 1 Trial**

- 1A Dose Escalation: Completed in 12 months
- 1B Dose Expansion: Completed recruitment for pancreatic adenocarcinoma (PDAC) arm
- **3 Partial Responses (PR) in PDAC, 2 PRs in gastric-oesophageal carcinoma**



**3** Lead Compounds Declared

Entered in 2024



**6** Pre-portfolio projects

**4** Portfolio projects

**2** Platforms<sup>2</sup>



**2** Technology Disclosures Filed

**1** Priority Patent Filed

## Engaging & Enabling Industry



**8** Local Biotech & Pharma Engaged

100% Client Satisfaction



**5** Industry Collaborations

Committed Industry Research Spending for new collaborations in FY24 exceeds \$650K<sup>3</sup>

Ongoing BD&L Engagements with **130** companies including

**12** of the top 20<sup>4</sup> Pharma companies



**28** Venture funds

**78** Biotechs (including 45 at C-suite level)

<sup>1</sup> Singapore Therapeutics Development Review

<sup>2</sup> Platform: proprietary technology, method or approach that enables the discovery and development of therapeutics

<sup>3</sup> Includes only R&D spending in Singapore committed by companies

<sup>4</sup> Based on total sales revenue in 2024